Business Wire

Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth

Share

After nearly a decade of public-private collaboration, Ferring Pharmaceuticals today announces the first use of heat-stable carbetocin (Carbetocin Ferring) for the prevention of excessive bleeding after birth, known as postpartum haemorrhage (PPH). Heat-stable carbetocin is now available for use in healthcare facilities across India, in the prevention of excessive bleeding following vaginal and caesarean section births.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210725005005/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sarika – the first woman to receive heat-stable carbetocin, with her husband, newborn son and the first doctor to administer, Dr Yeshita V Pujar, Karnataka, India (Photo: Business Wire)

This major maternal health milestone has been eagerly awaited since the publication of the CHAMPION (Carbetocin HAeMorrhage PreventION) trial results in 20182 - a study led by the World Health Organization (WHO) as part of a collaboration with MSD for Mothers* and Ferring Pharmaceuticals. These data contributed to heat-stable carbetocin being added to the WHO Model List of Essential Medicines (EML),3 as well as an update in the WHO’s recommendations on uterotonics for the prevention of excessive bleeding after birth.4

“Today is an unforgettable milestone for maternal health in India. Every 5 minutes a woman dies during pregnancy or childbirth across India and excessive bleeding after childbirth is responsible for 30% of these deaths,” said Dr Shivaprasad Goudar, Professor of Physiology, J N Medical College & Director-Research, KLE Academy of Higher Education and Research, Belagavi, India and Principal Investigator (India) for the CHAMPION clinical trial. “It is truly traumatic to see a mother die due to a preventable cause, and the impact this has on the family goes beyond the initial loss. Because this new formulation is not dependent on being stored or transported in refrigerators, it is a real step forward to ensuring women, especially in remote areas, can access high quality maternity care. The last few months have been an incredibly challenging time for India as we tackle the COVID-19 pandemic but it remains vital to prioritise maternal health to ensure the safety of expectant mothers at risk of excessive bleeding after childbirth.”

Until now, the first-choice drug for preventing excessive bleeding after birth required storage and transportation at 2–8°C, typically in a refrigerator to maintain its effectiveness. This is often difficult in low- and lower-middle income countries, many of which have hot climates and unpredictable power sources. As a result, many women are deprived of access to a lifesaving drug or the drug being less predictable and potentially being less effective because of exposure to heat. Carbetocin Ferring is a heat-stable formulation with predictable quality offering an additional option for healthcare professionals in preventing excessive bleeding after childbirth.

“At Ferring, we believe that every woman giving birth should have access to quality care and medicines to help them build families, regardless of where they live. Reaching the moment where the first woman receives heat-stable carbetocin is a landmark achievement for Ferring, which would not have been possible without collaboration, and we would like to thank all those involved, especially the patients in the clinical trial,” said Per Falk, President of Ferring Pharmaceuticals. “While we are hugely proud of achieving this milestone, our work will not stop here. Ferring is committed to supporting access to heat-stable carbetocin across the world in other low- and lower-middle income countries, so that we are closer to the vision that no woman dies giving life.”

Carbetocin Ferring was first approved in 2020, under the Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products (MAGHP), aimed to make essential medicines available faster for patients in low- and middle-income countries.5,6 Since then, besides India, Carbetocin Ferring has been approved in South Sudan, Sierra Leone – the countries with the first and third highest rates of maternal mortality in the world respectively, and Tanzania.7 Ferring and key partners are working to secure additional national registrations, to bring heat-stable carbetocin to the public sector of all low- and lower-middle income countries, where the burden of maternal mortality and cases of PPH are greatest.

Alongside it’s listing in the WHO Essential Medicines List, heat-stable carbetocin has been included in the UNFPA Product Catalogue for “quality-assured commodities related to reproductive health, census and humanitarian response”.8,9

* MSD for Mothers is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

ENDS

Notes to Editors

About Carbetocin Ferring

Globally, PPH causes approximately 70,000 deaths each year1 – with over 90% of deaths from PPH occurring in low- and lower-middle income countries.7 Carbetocin Ferring is a heat-stable formulation of carbetocin, a uterotonic medicine for the prevention of PPH in all births.3 It is administered in a single dose. Carbetocin Ferring was developed by Ferring Pharmaceuticals to address limitations in refrigeration and cold-chain transport of medicines in low- and lower-middle income countries. Heat-stable carbetocin is recommended by the World Health Organization in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics.10 It is licensed for the prevention of postpartum haemorrhage due to uterine atony after childbirth, following all births. Carbetocin Ferring is available at a sustainable access price for use in public-sector healthcare facilities in low- and lower-middle income countries.11 The availability of Carbetocin Ferring is subject to regulatory review and approval in relevant countries.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build healthy families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

References


1 Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2(6):e323-e333. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed: July 2021
2 Widmer M, et al. Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. N Engl J Med 2018; 379:743-752
DOI: 10.1056/NEJMoa1805489
3 WHO Model List of Essential Medicines. Available at: https://apps.who.int/iris/handle/10665/325771 Last accessed: July 2021
4 WHO. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Available at: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1 Last accessed July 2021
5 Swissmedic. First MAGHP approval in Switzerland. Available at: https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/informationen/first-maghp-approval-inswitzerland.html Last accessed: July 2021
6 Swissmedic. Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products (MAGHP). Available at: https://www.swissmedic.ch/swissmedic/en/home/about-us/development-cooperation/marketing-authorisation-for-global-health-products.html Last accessed: July 2021
7 World Health Organization. Trends in maternal mortality 2000 to 2017. 2019. Available at: https://apps.who.int/iris/bitstream/handle/10665/327596/WHO-RHR-19.23-eng.pdf Last accessed: July 2021
8 WHO Model List of Essential Medicines. Available at: https://apps.who.int/iris/handle/10665/325771 Last accessed: July 2021
9 UNFPA.UNFPA Product Catalog. Available at https://www.unfpaprocurement.org/products Last accessed: July 2021
10 WHO. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Available at: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1 Last accessed: July 2021
11 Ferring. 2019. Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries. Available at: https://www.ferring.com/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries/ Last accessed July 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information, please contact

Bhavin Vaid
Head of Corporate Communications
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Victoria Dacker
Associate Director, 90TEN
+44 7739 358 189 (mobile)
victoria.dacker@90ten.co.uk

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health27.9.2021 06:45:00 CEST | Press release

Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today announces an agreement with Novo Nordisk, a world leader in diabetes care, for the development and distribution (pending successful development) of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes. Mallya is a Bluetooth enabled smart add-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software. Mallya helps people with diabetes maintain a reliable dose log, using technology to help improve understanding and allowing people to dose with confidence. Most Novo Nordisk's insulins are offered with the FlexTouch pen, and it is part of the launch map for all new insulins. A specific version of Mallya will be developed for FlexTouch, the first prefilled insulin delivery device with

New Study Evaluates the Feasibility of Using Masimo EMMA ® Capnography on Mechanically Ventilated Neonates27.9.2021 01:00:00 CEST | Press release

Masimo (NASDAQ: MASI) today announced the findings of a study published in the European Journal of Pediatrics in which Dr. Masashi Hotta and colleagues at the Osaka Women’s and Children’s Hospital in Japan found that the Masimo EMMA® Portable Capnograph “may be considered an effective monitoring device” for mechanically ventilated preterm infants (neonates).1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210926005040/en/ Masimo EMMA® (Photo: Business Wire) Noting the importance of maintaining an appropriate range of partial pressure of arterial carbon dioxide (PaCO2) in preterm infants, especially while undergoing mechanical ventilation in the neonatal intensive care unit (NICU), the researchers sought to evaluate whether noninvasively monitoring end-tidal carbon dioxide (EtCO2) with EMMA could help clinicians maintain neonatal PaCO2 in the delivery room. They chose EMMA not only because of its portability but because it of

Spirit of Wipro Run Brings Together Participants From Over 35 Countries26.9.2021 14:57:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today organized the 16th annual ‘Spirit of Wipro’ (SOW) Run, drawing thousands of participants from over 35 countries to run together in spirit. For the past sixteen years, Wiproites around the world have come together to celebrate Wipro’s core values. The annual SOW run aims to inspire employees to be responsible citizens of the world. This year’s theme was “Together. To greatness,” inspired by the resilience demonstrated by Wiproites in a year of unprecedented disruption. Along with outperforming across all business parameters, Wipro teams have remained committed to supporting their colleagues and creating a lasting social impact across communities. Like last year, this year’s race was also virtual, and runners strictly adhered to the local COVID-19 guidelines and safety protocols while participating in the event. Even under these conditions,

Pencil Lab Inks Debut in ADIHEX 202125.9.2021 12:04:00 CEST | Press release

The 18th edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) on September 27 - October 3 marks an opportune platform for Pencil Lab Design Studio’s first major participation in the massive event, the largest of its kind in the Middle East and Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210925005016/en/ Pencil Lab Inks Debut in ADIHEX 2021 (Photo: AETOSWire) Featuring more than 800 brands and companies, the event is held under the theme of ‘Sustainability and Heritage… A Reborn Aspiration’, highlighting heritage, culture and authentic sports and their strong relation with Arab history. As part of its inaugural participation in a major exhibition as a company, Pencil Lab, a UAE initiative, will showcase their artworks with three large oil paintings by Pencil Lab’s citizen artist, to highlight the strong connection of arts, like painting and photography, to Arab history and civilization.

DXC Technology Completes Refinancing Actions24.9.2021 22:30:00 CEST | Press release

DXC Technology Company (NYSE: DXC) (“DXC”) today announced the completion of its refinancing. DXC previously completed the offering of €1.35 billion Senior Notes priced on September 2, 2021 and $1.35 billion Senior Notes priced on September 7, 2021. DXC completed redemption of $2.5 billion principal of (i) EUR term loan in the amount of €400 million due FY23 and FY24, (ii) $500 million 4.25% Senior notes due FY25, (iii) £250 million 2.75% Senior notes due FY25, (iv) $467 million 4.125% Senior notes due FY26, (v) $500 million 4.75% Senior notes due FY28, and (vi) $234 million Senior notes due FY30. The applicable make whole premium for these redemptions was $300 million and accrued and unpaid interest was $40 million. Ken Sharp, Chief Financial Officer, DXC commented: “Our opportunistic debt refinancing of $2.5 billion of our high coupon debt further solidifies our financial foundation by extending our debt maturities, lowering our maturity towers and reducing our ongoing interest expen

Schlumberger Announces Third-Quarter 2021 Results Conference Call24.9.2021 16:00:00 CEST | Press release

Schlumberger Limited (NYSE:SLB) will hold a conference call on October 22, 2021 to discuss the results for the third quarter ending September 30, 2021. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 8858313. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until November 22, 2021, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402

Tradeweb Successfully Completes its First Southbound Bond Connect Transactions24.9.2021 14:07:00 CEST | Press release

Tradeweb Markets Inc. (Nasdaq: TW), a leading global operator of electronic marketplaces for rates, credit, equities and money markets, today announced it has completed its first Southbound Bond Connect transactions via the trading link between Tradeweb and China Foreign Exchange Trade System (CFETS). “Southbound Bond Connect is the latest evolutionary step for China’s financial market, providing domestic investors with more flexibility and choice when trading offshore bonds,” said Lee Olesky, CEO of Tradeweb Markets. “Together with CFETS, our goal is to better meet onshore investors’ demand for streamlined access to global investment. We will continue to focus on further enhancing the trading link by deploying new innovative trading functionality, just as we did with the Northbound leg of Bond Connect.” Southbound Bond Connect facilitates fixed income portfolio diversification for institutional investors in China. Tradeweb collaborates closely with CFETS to create a uniform trading ex